The stock price of Taysha Gene Therapies Inc (NASDAQ: TSHA) has plunged by -6.55 when compared to previous closing price of 1.68, but the company has seen a -10.29% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2023-11-14 that Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants Hayleigh Collins – Director and Head of Corporate Communications Sean Nolan – Chief Executive Officer Sukumar Nagendran – President and Head of Research and Development Kamran Alam – Chief Financial Officer Conference Call Participants Whitney Ijem – Canaccord Genuity Kristen Kluska – Cantor Fitzgerald Salveen Richter – Goldman Sachs Gil Blum – Needham & Co Yanan Zhu – Wells Fargo Securities Jack Allen – Baird Joon Lee – Truist Securities Silvan Tuerkcan – JMP Securities Operator Good afternoon and welcome to the Taysha Gene Therapies Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
Is It Worth Investing in Taysha Gene Therapies Inc (NASDAQ: TSHA) Right Now?
while the 36-month beta value is -0.11.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The average price point forecasted by analysts for Taysha Gene Therapies Inc (TSHA) is $5.50, which is $3.93 above the current market price. The public float for TSHA is 115.89M, and currently, short sellers hold a 8.42% ratio of that floaft. The average trading volume of TSHA on November 17, 2023 was 2.89M shares.
TSHA’s Market Performance
TSHA’s stock has seen a -10.29% decrease for the week, with a -26.64% drop in the past month and a -18.23% fall in the past quarter. The volatility ratio for the week is 27.67%, and the volatility levels for the past 30 days are at 14.11% for Taysha Gene Therapies Inc The simple moving average for the last 20 days is -25.92% for TSHA stock, with a simple moving average of 13.25% for the last 200 days.
Analysts’ Opinion of TSHA
Many brokerage firms have already submitted their reports for TSHA stocks, with Jefferies repeating the rating for TSHA by listing it as a “Hold.” The predicted price for TSHA in the upcoming period, according to Jefferies is $1.50 based on the research report published on February 01, 2023 of the current year 2023.
TSHA Trading at -38.87% from the 50-Day Moving Average
After a stumble in the market that brought TSHA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.64% of loss for the given period.
Volatility was left at 14.11%, however, over the last 30 days, the volatility rate increased by 27.67%, as shares sank -24.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -57.10% lower at present.
During the last 5 trading sessions, TSHA fell by -10.29%, which changed the moving average for the period of 200-days by +29.75% in comparison to the 20-day moving average, which settled at $2.0942. In addition, Taysha Gene Therapies Inc saw -30.53% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at TSHA starting from Alam Kamran, who sale 33,000 shares at the price of $2.33 back on Aug 24. After this action, Alam Kamran now owns 258,042 shares of Taysha Gene Therapies Inc, valued at $76,890 using the latest closing price.
Manning Paul B, the 10% Owner of Taysha Gene Therapies Inc, purchase 16,466,667 shares at $0.90 during a trade that took place back on Aug 16, which means that Manning Paul B is holding 16,466,667 shares at $14,820,000 based on the most recent closing price.
Stock Fundamentals for TSHA
Current profitability levels for the company are sitting at:
- -5037.05 for the present operating margin
- +0.60 for the gross margin
The net margin for Taysha Gene Therapies Inc stands at -6635.25. The total capital return value is set at -114.91, while invested capital returns managed to touch -152.42. Equity return is now at value -746.43, with -139.98 for asset returns.
Based on Taysha Gene Therapies Inc (TSHA), the company’s capital structure generated 6,314.86 points at debt to equity in total, while total debt to capital is 98.44. Total debt to assets is 46.59, with long-term debt to equity ratio resting at 6,154.58. Finally, the long-term debt to capital ratio is 95.94.
When we switch over and look at the enterprise to sales, we see a ratio of 19.94, with the company’s debt to enterprise value settled at 0.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.52.
In a nutshell, Taysha Gene Therapies Inc (TSHA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.